| 產(chǎn)品編號 | bsm-61288R |
| 英文名稱 | Cyclooxygenase 1 Recombinant Rabbit mAb |
| 中文名稱 | 前列腺素氧化環(huán)化酶1重組兔單抗 |
| 別 名 | COX-1; COX1; COX3; Cyclooxygenase-1; PCOX1; PGG/HS; PGH synthase 1; PGH1; PGHS1; PHS1; Prostaglandin G/H synthase 1; Prostaglandin H2 synthase 1; PTGHS; PTGS1. |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 交叉反應(yīng) | Human,Mouse,Rat |
| 產(chǎn)品應(yīng)用 | WB=1:1000-1:2000,IHC-P=1:100-1:200,IHC-F=1:100-1:200,IF=1:50-1:200,Flow-Cyt=1:20-1:100,ICC/IF=1:50-1:200,IP=1:20-1:50
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 69 kDa |
| 檢測分子量 | 70 |
| 性 狀 | Liquid |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human COX 1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| 保存條件 | Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. SWISS: P23219 Gene ID: 5742 合成與降解（Synthesis and Degradation） COX1 前列腺素氧化環(huán)化酶-是前列腺素合成的關(guān)鍵酶之一，為誘導(dǎo)性酶，他參與細(xì)胞對生長因子、腫瘤促進(jìn)因子和細(xì)胞因子的反應(yīng)，這些因子均能誘導(dǎo)COX1表達(dá)，它也參與前列腺素的合成。 |
| 產(chǎn)品圖片 |
Western blot analysis of A431 cell lysate. Using Cyclooxygenase 1 (bsm-61288R) monoclonal antibody at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
